← Back to Delvant

Comparison

Delvant vs IQVIA Consulting

IQVIA Consulting runs the largest healthcare strategy practice in the market, sitting on a deep proprietary data stack. Delvant ships bounded custom-scoped intelligence in 5-15 business days. Different shapes of work, different price points, often complementary. This page is for teams choosing between a multi-month consulting engagement and a commissioned single-question deliverable.

Last updated 2026-05-16. Snapshot based on public information; refreshed quarterly.

What each one is

IQVIA Consulting is the strategy and advisory practice inside IQVIA Holdings (NYSE: IQV, formed from the 2016 Quintiles + IMS Health merger). The practice spans commercial strategy, R&D strategy, market access, real-world evidence, patient services, launch planning, and operations. Engagements are typically partner-led, run 8-16 weeks, and draw on IQVIA's proprietary data assets (anonymised claims, electronic medical records, prescription data, clinical trial intelligence) plus primary research and expert interviews. Pricing is not publicly disclosed; project quotes for healthcare strategy work at IQVIA Consulting and peers (McKinsey LSP, Bain Healthcare, BCG, ZS, Putnam, Trinity, L.E.K., Health Advances) typically range from low six figures USD for narrow scopes to seven figures for global launch or M&A work.

Delvant is a bounded custom-intelligence service. Each engagement starts from one or two specific questions a buyer cannot answer with a templated report or a database query, scopes the comparator set, runs a fresh search against locked anchor sources (ClinicalTrials.gov, EMA, FDA, PubMed, EHA, ASH, EULAR, AACR, ASCO, ESMO), tags every claim by provenance tier (Sourced, Inferred, Opinion, Hedged), and ships a 10-30 page deliverable in 5-15 business days. Tier 1 briefs start at EUR 3,500. Tier 2 strategic dossiers run EUR 12,000-35,000.

Side-by-side

Dimension IQVIA Consulting Delvant
Product shape Partner-led strategy engagement. Multi-workstream, multi-deliverable. Steering committee + workshops + final readout. Bounded custom-scoped deliverable. One-to-three commissioned questions per engagement. Single fixed PDF + slide-deck output.
Therapeutic area scope Broad. All major TAs across oncology, autoimmune, cardiovascular, neurology, rare disease, vaccines, gene/cell therapy. Narrow. Core: rare hematology, immune cytopenias (ITP, AIHA, HDFN), plasma-derived therapeutics. Adjacent: rare oncology, IgG autoimmune, transplant.
Methodology depth Deep. Combines IQVIA proprietary data (claims, EMR, prescription), primary research, KOL interviews, advisory boards, country-level analytics. Senior partner oversight throughout. Focused. AI-assisted retrieval + human synthesis against locked anchor sources. Per-claim tier tags (Sourced / Inferred / Opinion / Hedged) visible inline. No primary research on T1; KOL probe optional on T2.
Citation discipline References listed at deliverable level. Methodology section describes inputs. Per-claim source mapping not exposed by default. Every Sourced claim re-verified at the cited URL during Gate A pass. Page-locked references on every assertion.
Primary research + KOL access Core capability. Global KOL networks, payer interviews, patient research, advisory boards run in-house. Limited by design. T2 includes a small KOL probe set (3-6 interviews) when scoped; T1 is desk-research only. Delvant is not a primary-research shop.
Turnaround 8-16 weeks typical for a strategy engagement. Steering rhythm: weekly partner check-ins, mid-point readout, final. 5 business days (T1). 10-15 business days (T2). Fixed schedule, no rush-fee compression.
Indicative price (public) Not publicly disclosed. Healthcare strategy engagements at IQVIA Consulting and peer firms typically land between USD 250K and USD 2M+, scoped per project. From EUR 3,500 (T1, 1 question, 10-15 pages). EUR 12,000-35,000 (T2, 2-3 questions, 20-30 pages).
Team shape Partner + engagement manager + 2-4 associates + subject-matter experts. Steering committee on client side. Single accountable owner per engagement (founder-led at current stage). External peer pass + LLM-council adversarial review built into the gates.
AI methodology AI capabilities deployed across IQVIA platform products; consulting integrates these where applicable. Per-engagement AI use disclosed during scoping. AI-assisted retrieval and synthesis under documented human oversight; Gate A re-verifies every Sourced claim, Gate B runs LLM-council adversarial review. EU AI Act Article 4 deployer posture disclosed.
Buyer fit Large pharma + mid-cap biotech commercial leadership, R&D heads, market access leads. Decisions that touch EUR 50M+ in revenue or a major launch / M&A move. Medical affairs, BD search-and-evaluation, small-biotech CMOs, life-sciences analysts who need a single sharp comparator answer with audit-grade citation, fast.

When to pick which

IQVIA Consulting is a better fit when

  • The decision is high-stakes and global: a launch, an acquisition, a portfolio reshape.
  • You need primary research at scale (KOL panels, payer interviews, patient research, advisory boards) integrated into the analysis.
  • The question requires IQVIA's proprietary data assets (anonymised claims, EMR, longitudinal prescription panels).
  • You need a partner-led team you can run a steering committee with for 8-16 weeks.
  • The budget for the question is six to seven figures and the timeline allows it.

Delvant is a better fit when

  • You have one or two precise comparator questions and need an answer in days, not months.
  • The decision is medical-affairs or BD-led, not a full launch / M&A engagement.
  • You need every claim tier-tagged and citation-verified before sharing internally or with a committee.
  • Your TA is in our core: rare hematology, immune cytopenias, plasma-derived, adjacent rare oncology and IgG autoimmune.
  • The question budget sits between EUR 3,500 and EUR 35,000, not between USD 250K and 2M.

Where Delvant deliberately does not compete

Delvant is not a strategy consultancy. If your question requires 8-16 weeks of partner-led senior advisory time, integrated primary research at scale, payer and KOL panels run in-house, and a steering-committee cadence, you should commission IQVIA Consulting (or McKinsey LSP, Bain Healthcare, BCG, ZS, Putnam, Trinity, L.E.K., Health Advances). Delvant does not replace that work; it solves a different problem.

Delvant is also not a database. There is no log-in, no live pipeline tracker, no proprietary claims or EMR data. If your team needs a standing query layer across thousands of assets every week, a syndicated stack like Citeline, GlobalData, Evaluate, or Clarivate Cortellis is the right shape of tool. Delvant covers the gap between those two extremes: bounded custom work at 5-15 business day turnaround, EUR 3,500-35,000, narrow TA, audit-grade citation.

Honest note on positioning. Delvant is not a cheaper IQVIA Consulting. The two are different shapes of intelligence work and frequently complement each other. A medical affairs team might commission a Delvant T2 to answer a single comparator question in two weeks, then later run a full IQVIA Consulting engagement for the launch strategy that surrounds it. We are built to be useful for the questions that do not need the full consultancy treatment, and we point clients toward IQVIA Consulting or peers when the question actually does.

Not sure which fits your question?

30-minute scoping call. We will tell you whether a Delvant T1 or T2 fits, or whether you should be commissioning a multi-month consultancy engagement. Honest fit calls only.

Book a scoping call See engagement tiers